UY27823A1 - Nueva formulación para la administración parenteral de un bloqueante del canal del na - Google Patents

Nueva formulación para la administración parenteral de un bloqueante del canal del na

Info

Publication number
UY27823A1
UY27823A1 UY27823A UY27823A UY27823A1 UY 27823 A1 UY27823 A1 UY 27823A1 UY 27823 A UY27823 A UY 27823A UY 27823 A UY27823 A UY 27823A UY 27823 A1 UY27823 A1 UY 27823A1
Authority
UY
Uruguay
Prior art keywords
parenteral administration
del
blocker
canal
new formulation
Prior art date
Application number
UY27823A
Other languages
English (en)
Inventor
Dr Bernd Kruss
Annerose Mauz
Karin Ruehr
Jean Marie Stassen
Claus Veit
Dr Klaus Wagner
Original Assignee
Boehringer Ingelheim Pharma
Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Co Kg filed Critical Boehringer Ingelheim Pharma
Publication of UY27823A1 publication Critical patent/UY27823A1/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a una nueva formulación que contiene BIII 890 o una de sus sales farmacológicamente aceptables, para administración por vía parenteral.
UY27823A 2002-05-29 2003-05-27 Nueva formulación para la administración parenteral de un bloqueante del canal del na UY27823A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10223783A DE10223783A1 (de) 2002-05-29 2002-05-29 Neue Formulierung zur parenteralen Applikation eines Na-Kanal-Blockers

Publications (1)

Publication Number Publication Date
UY27823A1 true UY27823A1 (es) 2003-12-31

Family

ID=29432393

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27823A UY27823A1 (es) 2002-05-29 2003-05-27 Nueva formulación para la administración parenteral de un bloqueante del canal del na

Country Status (12)

Country Link
EP (1) EP1511517B1 (es)
JP (1) JP2005527615A (es)
AR (1) AR040134A1 (es)
AT (1) ATE373492T1 (es)
AU (1) AU2003237664A1 (es)
CA (1) CA2487150A1 (es)
DE (2) DE10223783A1 (es)
ES (1) ES2294295T3 (es)
PE (1) PE20040066A1 (es)
TW (1) TW200400029A (es)
UY (1) UY27823A1 (es)
WO (1) WO2003099336A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4239877C1 (de) * 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
DE4313408A1 (de) * 1993-04-23 1994-10-27 Boehringer Mannheim Gmbh Cyclodextrin-Biocid-Komplex
FR2713934B1 (fr) * 1993-12-22 1996-01-12 Commissariat Energie Atomique Utilisation de cyclodextrines aminées pour la solubilisation aqueuse de composés hydrophobes, en particulier de molécules pharmaceutiquement actives.
DE19740110A1 (de) * 1997-09-12 1999-03-18 Boehringer Ingelheim Pharma Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6565880B2 (en) * 2000-07-24 2003-05-20 Boehringer Ingelheim Pharmaceuticals, Inc. Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea
DE10223784A1 (de) * 2002-05-29 2003-12-11 Boehringer Ingelheim Pharma Neue Formulierung zur parenteralen Applikation von Crobenetine

Also Published As

Publication number Publication date
CA2487150A1 (en) 2003-12-04
EP1511517B1 (de) 2007-09-19
PE20040066A1 (es) 2004-03-22
ES2294295T3 (es) 2008-04-01
ATE373492T1 (de) 2007-10-15
DE50308227D1 (de) 2007-10-31
AU2003237664A1 (en) 2003-12-12
WO2003099336A1 (de) 2003-12-04
DE10223783A1 (de) 2003-12-11
EP1511517A1 (de) 2005-03-09
JP2005527615A (ja) 2005-09-15
AR040134A1 (es) 2005-03-16
TW200400029A (en) 2004-01-01

Similar Documents

Publication Publication Date Title
HN2003000408A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos.
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
UY26754A1 (es) Derivados de la 1, 3, 8, -triaza-spiro (4,5) decan-4-ona
UY28348A1 (es) Compuestos novedosos
NI200900076A (es) Nuevos derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, método para su preparación, productos farmacéuticos que comprenden estos compuestos y su uso.
ECSP066291A (es) Sistemas emulsionantes que contienen derivados de azetidina
NO20064808L (no) Orale matrixformuleringer med licarbazepin
BRPI0112375B8 (pt) aplidinas como derivados antitumorais
NO20064783L (no) Opplosningstabeletter med licarbazepin
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
EA200600590A1 (ru) Фармацевтические композиции модафинила с модифицированным высвобождением
DK0842165T3 (da) Thiazolidin-4-carboxylsyrederivater som cytobeskyttende midler
CR7648A (es) Microcapsulas para la liberacion retardada y controlada del perindropil
ITRM20030355A1 (it) Composti ad attivita' citotossica derivati della combretastatina.
UY27461A1 (es) Formas pseudopolimorficas de cardevilol.
ECSP066292A (es) Sistemas semi-sólidos que contienen derivados de azetidina
UY27823A1 (es) Nueva formulación para la administración parenteral de un bloqueante del canal del na
UY26718A1 (es) Uso de compuestos de 1-amino-5-fenilpentano-3-ol y/o 1-amino-6-fenilhexano-3-ol para la preparación de un medicamento con efecto antagonista de n-metil-d-aspartato- (nmda)
UY27824A1 (es) Nueva formulación para la administración parenteral de crobenetina.
HN2001000119A (es) S-metil-dihidro -ziprasidona para el tratamiento de trastornos psiquiatricos y oculares.
PT1052995E (pt) Composicao farmaceutica para a administracao por via nasal de tiocolchicosido
ECSP034708A (es) Nueva sal de benzoilguanidina
BR0105939A (pt) Método para a produção de derivados de citidina
EA200600172A1 (ru) Фармацевтическая композиция для интраназального введения пирибедила
GT199800008A (es) Procedimiento para la preparacion de un derivado de tetrahidropiridina.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150223